title: Analysis of circulating tumor cells in patients with triple negative breast cancer during preoperative chemotherapy.
abstract: The presence of circulating tumor cells in the blood of patients with triple negative breast cancer (early and locally advanced cancer) before and after preoperative chemotherapy was assessed using expression markers. Before therapy, circulating tumor cells were detected in 5 of 13 (38%) patients with early cancer and in 7 of 17 (41.2%) patients with locally advanced cancer. After therapy, the circulating immune cells were detected in one patient with locally advanced cancer, who had no circulating cells before therapy. The tumor was resistant to chemotherapy and the disease progressed. The detected circulating tumor cells were HER-2-positive, while the primary tumor was HER-2-negative. It was concluded that the circulating immune cells can be a potential marker of the efficiency of therapy and predictors of the disease course, while their phenotype can differ from the phenotype of the primary tumor.
authors.affiliation: Moscow Physico-Technical Institute (State University), Moscow, Russia, avlavrov@yandex.ru.
authors.forename: A V
authors.initials: AV
authors.lastname: Lavrov
authors.forename: Zh I
authors.initials: ZhI
authors.lastname: Zubtsova
authors.forename: D A
authors.initials: DA
authors.lastname: Zubtsov
authors.forename: M A
authors.initials: MA
authors.lastname: Frolova
authors.forename: E O
authors.initials: EO
authors.lastname: Ignatova
authors.forename: M A
authors.initials: MA
authors.lastname: Skrypnikova
authors.forename: E V
authors.initials: EV
authors.lastname: Malysheva
authors.forename: E V
authors.initials: EV
authors.lastname: Legchenko
authors.forename: A V
authors.initials: AV
authors.lastname: Petrovskii
authors.forename: I A
authors.initials: IA
authors.lastname: Utyashev
authors.forename: S A
authors.initials: SA
authors.lastname: Tyulyandin
authors.forename: D V
authors.initials: DV
authors.lastname: Gol'dshtein
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002278:Carcinoma in Situ / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D019008:Drug Resistance, Neoplasm; D005260:Female; D015870:Gene Expression; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009360:Neoplastic Cells, Circulating / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human